Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UDP-glucose glycoprotein glucosyltransferase 2 (UGGT2) is an ER-resident glucosyltransferase and quality control sensor protein. It selectively reglucosylates misfolded N-glycoproteins, enabling their reassociation with lectin chaperones which retain them in the ER and facilitate further folding attempts or target them for degradation if proper folding is not restored. Unlike its paralogue UGGT1, which modifies a broader range of glycoproteins including large plasma membrane proteins, UGGT2 is preferentially active against smaller soluble lysosomal proteins. The function of UGGT2 is essential in maintaining secretory pathway integrity, and its misregulation has been linked to protein folding diseases. No approved drugs currently target UGGT2 directly, but its activity is critical for the proper folding and quality control of many secreted and lysosomal proteins, and thus indirectly relevant to the efficacy and safety of therapeutic biologics.
Putative inhibitors or modulators would affect ER quality control and glycoprotein maturation (no known drugs)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UDP-glucose glycoprotein glucosyltransferase 2 (UGGT2).